Nektar Therapeutics
NKTR
201 hedge funds and large institutions have $3.44B invested in Nektar Therapeutics in 2017 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 73 increasing their positions, 70 reducing their positions, and 24 closing their positions.
600% more funds holding in top 10
Funds holding in top 10: 1 → 7 (+6)
145% more call options, than puts
Call options by funds: $32.8M | Put options by funds: $13.4M
93% more capital invested
Capital invested by funds: $1.78B → $3.44B (+$1.66B)
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
1% more funds holding
Funds holding: 199 → 201 (+2)
4% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 70
0.03% more ownership
Funds ownership: 6.33% → 6.36% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$300M |
| 2 |
JP Morgan Chase
New York
|
+$24.3M |
| 3 |
DFO
Duquesne Family Office
New York
|
+$9.97M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.51M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$18.8M |
| 2 |
BM
Bridger Management
New York
|
-$15.1M |
| 3 |
O
OppenheimerFunds
New York
|
-$14.9M |
| 4 |
Two Sigma Investments
New York
|
-$10.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$10.2M |
NKTR Hedge Fund Activity: Q1 2017 in Review
201 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2017, worth a combined $3.44B — up 93% from $1.78B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new NKTR positions and 24 closed out — a net gain of 9 holders — while 73 added to existing stakes and 70 trimmed.
The largest buyer was BlackRock, adding an estimated $300M. The largest seller was Granahan Investment Management, cutting an estimated $18.8M.
- 201 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2017, up from 199 in Q4 2016.
- Funds reported $3.44B of Nektar Therapeutics stock for Q1 2017, up 93% quarter-over-quarter.
- 33 funds opened new Nektar Therapeutics positions in Q1 2017 and 24 closed out, a net change of +9 holders.
- The largest Nektar Therapeutics buyer in Q1 2017 was BlackRock, an estimated $300M added.
- The largest Nektar Therapeutics seller in Q1 2017 was Granahan Investment Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q1 2017.